| MEDVET SCIENCE PTY. LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120196925 | Therapeutic and Diagnostic Molecules - The present invention relates to methods for modulating angiogenesis, comprising administering to a subject, or cells or tissue derived therefrom: (i) one or more miRNA, or precursors or variants thereof, wherein at least one of said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to inhibit angiogenesis; or (ii) one or more antagonists of a miRNA, wherein said miRNA comprises a seed region comprising the sequence UCACAGU (SEQ ID NO:37) to promote or induce angiogenesis. Also provided are methods of diagnosis of conditions associated with abnormal angiogenesis, or determining predisposition thereto. Suitable pharmaceutical compositions are also provided. | 08-02-2012 |
| 20110150884 | CRYSTALLINE COMPOSITION OF GM-CSF/GM-CSFR - The present invention relates generally to the field of crystallography. More particularly, the present invention provides crystalline forms of a complex between granulocyte macrophage-colony stimulating factor (GM-CSF) and its receptor (GM-CSFR). The present invention further provides methods for the design and selection of modulators of GM-CSF/GM-CSFR interaction and signaling as well as signaling of other cytokines. | 06-23-2011 |
| 20100310450 | METHOD OF DIAGNOSIS AND AGENTS USEFUL FOR SAME - The present invention relates generally to a method of screening for a neoplastic cell in a subject. More particularly, the present invention provides a method of screening for both viable neoplastic cells and, still further, cytotoxin induced neoplastic cell death by detecting the level of expression of La protein and/or gene by a cellular population in said subject or in a biological sample derived from said subject. The method of the present invention is useful in a range of applications including, but not limited to, diagnosing, prognosing or assessing a neoplastic condition, monitoring the progression of such a condition, assessing the effectiveness of a therapeutic agent or therapeutic regime and predicting the likelihood of a subject either progressing to a more advanced disease state or entering a remissive state. The present invention also provides diagnostic agents useful for detecting La protein and/or nucleic acid molecules. | 12-09-2010 |
| 20100260744 | REGULATING IL-4 AND IL-13 LEVELS BY BLOCKING HIGH AFFINITY BINDING BY IL-3, IL-5 AND GM-CSF TO THEIR COMMON RECEPTOR - A method of reducing IL-4 and/or IL-13 levels in the lung of a mammal with elevated levels thereof, includes the step of administering to the mammal an effective amount of a βc receptor blocker capable of blocking the binding of all three of IL-3, IL-5 and GM-CSF to the βc common chain to thereby reduce the IL-4 and/or IL-13 levels. | 10-14-2010 |
| 20100184779 | METHOD FOR OPTIMIZING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS - The present invention relates to a method for evaluating patients to help optimizing the treatment of chronic myeloid leukemia (CML) in a human patient population. More specifically, the method comprises the steps of (a) determining the OCT-1 Activity in pre-therapy blood of a warm-blooded animal suffering from CML, and (b) administering a daily dose between about 500 and 1200 mg of Imatinib mesylate to the warm-blooded animal suffering from CML showing an OCT-1 Activity corresponding to Imatinib intracellular concentration to below about 6.0 to 10.0 ng/200,000 cells, especially about 8.0 to 8.5 ng/200,000 cells. | 07-22-2010 |
| 20100135903 | USE OF A DNA DAMAGING AGENT AND A LIGAND FOR THE TREATMENT OF CANCER - The present invention relates generally to a method of treating a neoplastic condition and to agents useful for same. More particularly, the present invention is directed to a method of facilitating the treatment of a metastatic neoplastic tumour in a localised manner by effecting the exposure of neoplastic cell intra-cellular molecules, preferably intra-nuclear molecules, suitable for use as a therapeutic target. The co-localisation of tumour cells and metastases to discrete tissue locations thereby renders the method of the present invention useful in terms of the delivery of bystander-based therapy. | 06-03-2010 |
| 20100088775 | METHODS OF MODULATING EPITHELIAL-MESENCHYMAL TRANSITION AND MESENCHYMAL-EPITHELIAL TRANSITION IN CELLS AND AGENTS USEFUL FOR THE SAME - The present invention relates generally to the fields of treatment, prophylaxis and diagnosis of cell-based and fibrotic conditions in animals including mammals. More particularly, the present invention contemplates the use of agents which modulate epithelial-mesenchymal transition (EMT) processes and mesenchymal-epithelial transition (MET) processes and hence are useful in the treatment of a range of conditions including inhibiting metastasis of solid tumors and the development of fibrosis, treating metastatic disease and in promoting wound healing. Diagnostic protocols to assess EMT and MET or its stage of development also form part of the present invention. The EMT and MET modulating agents are also useful in regulating gene expression and, hence, represent useful therapeutic and research tools. | 04-08-2010 |
| 20090214420 | Method of Diagnosis and Treatment and Agents Useful for Same - The present invention relates generally to a method of screening for the level of neoplastic cell death in a subject. More particularly, the present invention provides a method of screening for the level of neoplastic cell death by detecting the level of expression of telomerase protein and/or gene by dead cells in said subject or in a biological sample derived from said subject. The method of the present invention is useful in a range of applications including, but not limited to, assessing a neoplastic condition, monitoring the progression of such a condition, assessing the effectiveness of a therapeutic agent or therapeutic regime and predicting the likelihood of a subject either progressing to a more advanced disease state or entering a remissive state. The present invention also provides diagnostic agents useful for detecting telomerase protein and/or nucleic acid molecules. | 08-27-2009 |
| 20080279897 | Method of Treating Cellular Damage - The present invention relates generally to a method of modulating hyperglycaemia-induced endothelial cell functioning and agents useful for same. More particularly, the present invention relates to a method of modulating hyperglycaemia-induced vascular endothelial cell functioning by modulating intracellular sphingosine kinase-mediated signalling. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of the adverse vascular endothelial cell functioning associated with conditions characterised by hyperglycaemia, and/or diabetes mellitus, per se. | 11-13-2008 |
| 20080279841 | Novel Therapeutic Molecular Variants And Uses Thereof - The present invention relates generally to a sphingosine kinase variant and to derivatives, analogues, chemical equivalents and mimetics thereof exhibiting reduced catalytic activity and, more particularly, to sphingosine kinase variants which exhibit a reduced capacity to phosphorylate sphingosine to sphingosine-1-phosphate. The present invention also contemplates genetic sequences encoding said sphingosine kinase variants and derivatives, analogues and mimetics thereof. The variants of the present invention are useful in a range of therapeutic and prophylactic applications. | 11-13-2008 |
